Neurofibromatosis type 1 and autism spectrum disorder

Shruti Garg; Jonathan Green; Kathy Leadbitter; Richard Emsley; Annukka Lehtonen; Gareth Evans; Susan M. Huson

doi:10.1542/peds.2013-1868

Neurofibromatosis type 1 and autism spectrum disorder

Shruti Garg, Jonathan Green, Kathy Leadbitter, Richard Emsley, Annukka Lehtonen, Gareth Evans, Susan M. Huson

Division of Neuroscience

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To determine the prevalence of autism spectrum disorder (ASD) in Neurofibromatosis Type 1 (NF1). METHODS: Second-phase population-based epidemiologic study using an allcase NF1 registry in a defined UK 4.1 million population area. A total of 109 (52.7%) of 207 responders from the initial screening phase were grouped by using the parent-rated Social Responsiveness Scale (SRS) as significant ASD (SRS≥76; n = 32), moderate ASD (SRS ≥ 60

Comment: https://www.research.manchester.ac.uk/portal/en/publications/realternative-explanations-for-high-rates-of-autism-symptomatology-in-neurofibromatosis-type-1(3465e7cc-9785-4459-bedc-55abe143a0fd).html

Original language	English
Pages (from-to)	e1642-e1648
Journal	Pediatrics
Volume	132
Issue number	6
DOIs	https://doi.org/10.1542/peds.2013-1868
Publication status	Published - Dec 2013

Keywords

Autism
Epidemiology
Neurofibromatosis type 1
Population

Access to Document

10.1542/peds.2013-1868

http://pediatrics.aappublications.org/content/132/6/e1642.full.pdf+html

Cite this

@article{f805aab4a3874048b65bd5acd0534cc0,

title = "Neurofibromatosis type 1 and autism spectrum disorder",

abstract = "OBJECTIVE: To determine the prevalence of autism spectrum disorder (ASD) in Neurofibromatosis Type 1 (NF1). METHODS: Second-phase population-based epidemiologic study using an allcase NF1 registry in a defined UK 4.1 million population area. A total of 109 (52.7%) of 207 responders from the initial screening phase were grouped by using the parent-rated Social Responsiveness Scale (SRS) as significant ASD (SRS≥76; n = 32), moderate ASD (SRS ≥ 60Comment: https://www.research.manchester.ac.uk/portal/en/publications/realternative-explanations-for-high-rates-of-autism-symptomatology-in-neurofibromatosis-type-1(3465e7cc-9785-4459-bedc-55abe143a0fd).html",

keywords = "Autism, Epidemiology, Neurofibromatosis type 1, Population",

author = "Shruti Garg and Jonathan Green and Kathy Leadbitter and Richard Emsley and Annukka Lehtonen and Gareth Evans and Huson, {Susan M.}",

year = "2013",

month = dec,

doi = "10.1542/peds.2013-1868",

language = "English",

volume = "132",

pages = "e1642--e1648",

journal = "Pediatrics",

issn = "0210-5721",

publisher = "American Academy of Pediatrics",

number = "6",

}

TY - JOUR

T1 - Neurofibromatosis type 1 and autism spectrum disorder

AU - Garg, Shruti

AU - Green, Jonathan

AU - Leadbitter, Kathy

AU - Emsley, Richard

AU - Lehtonen, Annukka

AU - Evans, Gareth

AU - Huson, Susan M.

PY - 2013/12

Y1 - 2013/12

N2 - OBJECTIVE: To determine the prevalence of autism spectrum disorder (ASD) in Neurofibromatosis Type 1 (NF1). METHODS: Second-phase population-based epidemiologic study using an allcase NF1 registry in a defined UK 4.1 million population area. A total of 109 (52.7%) of 207 responders from the initial screening phase were grouped by using the parent-rated Social Responsiveness Scale (SRS) as significant ASD (SRS≥76; n = 32), moderate ASD (SRS ≥ 60Comment: https://www.research.manchester.ac.uk/portal/en/publications/realternative-explanations-for-high-rates-of-autism-symptomatology-in-neurofibromatosis-type-1(3465e7cc-9785-4459-bedc-55abe143a0fd).html

AB - OBJECTIVE: To determine the prevalence of autism spectrum disorder (ASD) in Neurofibromatosis Type 1 (NF1). METHODS: Second-phase population-based epidemiologic study using an allcase NF1 registry in a defined UK 4.1 million population area. A total of 109 (52.7%) of 207 responders from the initial screening phase were grouped by using the parent-rated Social Responsiveness Scale (SRS) as significant ASD (SRS≥76; n = 32), moderate ASD (SRS ≥ 60Comment: https://www.research.manchester.ac.uk/portal/en/publications/realternative-explanations-for-high-rates-of-autism-symptomatology-in-neurofibromatosis-type-1(3465e7cc-9785-4459-bedc-55abe143a0fd).html

KW - Autism

KW - Epidemiology

KW - Neurofibromatosis type 1

KW - Population

UR - https://www.research.manchester.ac.uk/portal/en/publications/realternative-explanations-for-high-rates-of-autism-symptomatology-in-neurofibromatosis-type-1(3465e7cc-9785-4459-bedc-55abe143a0fd).html

U2 - 10.1542/peds.2013-1868

DO - 10.1542/peds.2013-1868

M3 - Article

C2 - 24190681

SN - 0210-5721

SN - 0031-4005

SN - 1098-4275

VL - 132

SP - e1642-e1648

JO - Pediatrics

JF - Pediatrics

IS - 6

ER -

Neurofibromatosis type 1 and autism spectrum disorder

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

SimvaStatin in Neurofibromatosis Type 1- Autism (SANTA)

Cite this

Neurofibromatosis type 1 and autism spectrum disorder

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Projects

SimvaStatin in Neurofibromatosis Type 1- Autism (SANTA)

Cite this